Novavax Says it Could Start Making Omicron-Specific Vaccine in January

Dec 2 (Reuters) – Novavax Inc said on Thursday it could begin commercial manufacturing of a COVID-19 vaccine tailored for the Omicron coronavirus variant in January next year, while it tests whether or not its current vaccine works against the variant.

Laboratory data expected in the coming weeks will show whether antibodies from individuals who have previously received Novavax’s COVID-19 shot can neutralize the variant, according to the company.

Novavax also said it has started developing an Omicron-specific spike protein antigen and will begin laboratory tests of a new vaccine to target the variant in a few weeks.

The Omicron coronavirus variant has shaken up markets and caused global alarm over concerns about whether it could evade protection provided by widely used vaccines and prolong the public health crisis.

Other vaccine makers including Moderna and Pfizer have also begun working on Omicron-tailored COVID-19 shots.

Novavax’s COVID-19 vaccine received its first emergency use approval in Indonesia in early November followed by the Philippines.

(Reporting by Amruta Khandekar; Editing by Shounak Dasgupta)

Reuters

Recent Posts

$50 Million for Administration? Odyssey Chosen to Run Texas School Voucher Program

Texas Comptroller Kelly Hancock announced Monday that…

19 hours ago

Wesley Hunt Enters Texas GOP Senate Race And Shakes Up 2026 Primary

Texas Republican Congressman Wesley Hunt announced Monday…

20 hours ago

Trey Trainor Launches Bid for Chip Roy’s Congressional Seat

Trey Trainor, a longtime ally of President…

20 hours ago

Texas Democrats Focus on Winning Back Working-Class Voters

As Texas Democrats prepare for the 2026…

2 days ago

Federal Court Slams the Brakes on Trump’s National Guard Move

President Donald Trump authorized the deployment of…

2 days ago

Conservatives Criticize Bad Bunny’s Super Bowl Halftime Selection

Texas Attorney General Ken Paxton is among…

3 days ago

This website uses cookies.